Specifically, in breast cancer, emerging biomarkers such as polo-like kinase (PLK) PLK 2, PLK3, and PLK5 have been validated as significant prognostic indicators through survival analysis utilizing the Kaplan–Meier Plotter database. Here, PLK2 is linked to breast cancer.